May 2022 – Osprey Capital Partners Inc. (“Osprey Capital”) is pleased to announce that NKS Health has completed a sale transaction to Green Shield Canada. Servicing 30,000 patients per year, NKS Health has a strong reputation for patient-focused care. The acquisition provides GSC with additional capability in managing drug costs for employers while enhancing patient health outcomes. Osprey Capital acted as exclusive financial advisor to NKS Health.
Established in 2007, NKS Health is a specialty pharmaceutical services company focused on the handling and service of injectable, infused, and biologic medications.
NKS Health provides high-quality service by strategically focusing on chronic autoimmune and neurological conditions, such as rheumatoid arthritis, gastrointestinal diseases, dermatological diseases, stroke rehabilitation, migraines, and multiple sclerosis.
“At NKS Health, we pride ourselves on helping patients with their specialty medications so that they have better access to care and a greater chance of positive outcomes,” adds Nancy Simonot, NKS Health CEO and Co-Founder. Partner and Co-Founder Steve Simonot adds: “Our management team, led by Kristen Ribble, is looking forward to being part of the GSC group of companies and having opportunities to do even more to support these patients.”
“We are excited to be going back to where it all started – our pharmacy roots,” says Mark Rolnick, EVP, Pharmacy Innovation and Patient Experience at GSC. “These acquisitions represent an important step in providing an industry-leading experience through an integrated set of services, including health case management for both chronic and complex diseases, adherence solutions, and pharmacy operations.”
Stephen Jakob, Managing Partner at Osprey Capital, “This was an exciting transaction because we were able to use our deep knowledge of the industry to assist in the preparation of the business which ultimately resulted in a great outcome for Nancy and Steven.”